Sign In
Buy XERS
Xeris Pharmaceuticals Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | -$0.0027 |
| EPS actual | $0.0100 |
| EPS Surprise | 464.96% |
| Revenue estimate | 79.833M |
| Revenue actual | 82.454M |
| Revenue Surprise | 3.28% |
| Release date | Mar 02, 2026 |
| EPS estimate | $0.0300 |
| EPS actual | $0.0600 |
| EPS Surprise | 100.00% |
| Revenue estimate | 82.2M |
| Revenue actual | 85.807M |
| Revenue Surprise | 4.39% |
| Release date | Nov 06, 2025 |
| EPS estimate | $0.0100 |
| EPS actual | $0.0035 |
| EPS Surprise | -65.00% |
| Revenue estimate | 86M |
| Revenue actual | 74.38M |
| Revenue Surprise | -13.51% |
| Release date | Aug 07, 2025 |
| EPS estimate | -$0.0300 |
| EPS actual | -$0.0100 |
| EPS Surprise | 66.67% |
| Revenue estimate | 72.25M |
| Revenue actual | 71.539M |
| Revenue Surprise | -0.98% |
Last 4 Quarters for Xeris Pharmaceuticals
Below you can see how XERS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 07, 2025 |
| Price on release | $6.60 |
| EPS estimate | -$0.0300 |
| EPS actual | -$0.0100 |
| EPS surprise | 66.67% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $5.38 |
| Aug 04, 2025 | $5.56 |
| Aug 05, 2025 | $5.48 |
| Aug 06, 2025 | $5.49 |
| Aug 07, 2025 | $6.60 |
| Aug 08, 2025 | $6.84 |
| Aug 11, 2025 | $7.20 |
| Aug 12, 2025 | $7.30 |
| Aug 13, 2025 | $7.28 |
| 4 days before | 22.68% |
| 4 days after | 10.30% |
| On release day | 3.64% |
| Change in period | 35.32% |
| Release date | Nov 06, 2025 |
| Price on release | $7.71 |
| EPS estimate | $0.0100 |
| EPS actual | $0.0035 |
| EPS surprise | -65.00% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $9.70 |
| Nov 03, 2025 | $9.90 |
| Nov 04, 2025 | $9.90 |
| Nov 05, 2025 | $9.87 |
| Nov 06, 2025 | $7.71 |
| Nov 07, 2025 | $7.43 |
| Nov 10, 2025 | $7.72 |
| Nov 11, 2025 | $7.44 |
| Nov 12, 2025 | $7.59 |
| 4 days before | -20.52% |
| 4 days after | -1.56% |
| On release day | -3.63% |
| Change in period | -21.75% |
| Release date | Mar 02, 2026 |
| Price on release | $6.02 |
| EPS estimate | $0.0300 |
| EPS actual | $0.0600 |
| EPS surprise | 100.00% |
| Date | Price |
|---|---|
| Feb 24, 2026 | $6.68 |
| Feb 25, 2026 | $6.66 |
| Feb 26, 2026 | $6.74 |
| Feb 27, 2026 | $6.12 |
| Mar 02, 2026 | $6.02 |
| Mar 03, 2026 | $5.94 |
| Mar 04, 2026 | $6.07 |
| Mar 05, 2026 | $6.04 |
| Mar 06, 2026 | $5.81 |
| 4 days before | -9.88% |
| 4 days after | -3.49% |
| On release day | -1.33% |
| Change in period | -13.02% |
| Release date | May 07, 2026 |
| Price on release | $6.63 |
| EPS estimate | -$0.0027 |
| EPS actual | $0.0100 |
| EPS surprise | 464.96% |
| Date | Price |
|---|---|
| May 01, 2026 | $6.28 |
| May 04, 2026 | $6.34 |
| May 05, 2026 | $6.23 |
| May 06, 2026 | $6.37 |
| May 07, 2026 | $6.63 |
| May 08, 2026 | $6.53 |
| May 11, 2026 | $6.14 |
| May 12, 2026 | $6.26 |
| May 13, 2026 | $6.43 |
| 4 days before | 5.57% |
| 4 days after | -3.02% |
| On release day | -1.51% |
| Change in period | 2.39% |
Xeris Pharmaceuticals Earnings Call Transcript Summary of Q1 2026
Xeris reported a strong start to 2026 with Q1 total revenue of $83.1M (net product revenue $82.5M), up ~38–43% year-over-year driven primarily by Recorlev, which nearly doubled to $49.8M (95% growth). Keveyis grew modestly (4% to ~$11.9M) and Gvoke was flat (~$20.8M) after Medicare-driven payer resets and higher out-of-pocket costs that temporarily depressed prescription fills. Management raised the low end of 2026 revenue guidance to $380M–$390M and reiterated confidence in continued momentum, particularly as the recently completed commercial expansion (now ~80 reps, ~12,000 HCP targets) ramps and begins to contribute more meaningfully in H2. Pipeline progress: XP-8121 (hypothyroidism candidate using XeriSol/device expertise) remains on track for Phase III initiation later this year, with a program review planned for the fall. Financial highlights: gross margin 87%, R&D up modestly as XP-8121 is advanced, SG&A rose reflecting commercial expansion, adjusted EBITDA positive ($15.1M) and net income of $2.2M in Q1. Management emphasized disciplined reinvestment for growth and optionality for further capital allocation, prioritizing reinvestment in the business and potential inorganic opportunities that align with commercial/R&D capabilities.
